MEDICUS PHARMA LTD (MDCX) Stock Price & Overview

NASDAQ:MDCX • CA58471K2020

Current stock price

0.402 USD
-0.01 (-2.9%)
At close:
0.4146 USD
+0.01 (+3.13%)
After Hours:

The current stock price of MDCX is 0.402 USD. Today MDCX is down by -2.9%. In the past month the price decreased by -26.32%. In the past year, price decreased by -89.95%.

MDCX Key Statistics

52-Week Range0.37 - 8.94
Current MDCX stock price positioned within its 52-week range.
1-Month Range0.3912 - 0.5438
Current MDCX stock price positioned within its 1-month range.
Market Cap
15.823M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-2.32
Dividend Yield
N/A

MDCX Stock Performance

Today
-2.9%
1 Week
-18.11%
1 Month
-26.32%
3 Months
-71.08%
Longer-term
6 Months -82.97%
1 Year -89.95%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

MDCX Stock Chart

MEDICUS PHARMA LTD / MDCX Daily stock chart

MDCX Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to MDCX. When comparing the yearly performance of all stocks, MDCX is a bad performer in the overall market: 99.05% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

MDCX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MDCX. While MDCX seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MDCX Earnings

Next Earnings DateMay 11, 2026
Last Earnings DateMar 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.83
Revenue Reported
EPS Surprise -430.70%
Revenue Surprise %

MDCX Forecast & Estimates

9 analysts have analysed MDCX and the average price target is 7.14 USD. This implies a price increase of 1676.12% is expected in the next year compared to the current price of 0.402.


Analysts
Analysts82.22
Price Target7.14 (1676.12%)
EPS Next Y72.3%
Revenue Next YearN/A

MDCX Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

MDCX Financial Highlights

Over the last trailing twelve months MDCX reported a non-GAAP Earnings per Share(EPS) of -2.32. The EPS decreased by -15.65% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-47.28M
Industry RankSector Rank
PM (TTM) N/A
ROA -835.67%
ROE -2201.6%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-361.11%
Sales Q2Q%N/A
EPS 1Y (TTM)-15.65%
Revenue 1Y (TTM)N/A

MDCX Ownership

Ownership
Inst Owners10.02%
Shares39.36M
Float32.09M
Ins Owners6.18%
Short Float %19.95%
Short Ratio0.77

About MDCX

Company Profile

MDCX logo image Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is headquartered in Conshohocken, Pennsylvania. The company went IPO on 2023-10-11. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The company is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.

Company Info

IPO: 2023-10-11

MEDICUS PHARMA LTD

300 Conshohocken State Rd., Suite 200

Conshohocken PENNSYLVANIA US

Employees: 16

MDCX Company Website

MDCX Investor Relations

Phone: 16105407515

MEDICUS PHARMA LTD / MDCX FAQ

Can you describe the business of MEDICUS PHARMA LTD?

Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is headquartered in Conshohocken, Pennsylvania. The company went IPO on 2023-10-11. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The company is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.


What is the current price of MDCX stock?

The current stock price of MDCX is 0.402 USD. The price decreased by -2.9% in the last trading session.


Does MEDICUS PHARMA LTD pay dividends?

MDCX does not pay a dividend.


What is the ChartMill rating of MEDICUS PHARMA LTD stock?

MDCX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Is MEDICUS PHARMA LTD (MDCX) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MDCX.


Can you provide the short interest for MDCX stock?

The outstanding short interest for MEDICUS PHARMA LTD (MDCX) is 19.95% of its float.